Hinsch Gylvin Lykke 4

What Happened

• Hinsch Gylvin Lykke, a director of ProQR Therapeutics N.V. (PRQR), received a grant of 14,495 derivative shares on June 2, 2026. The filing reports a $0.00 acquisition price (no cash paid). The instrument is a derivative award (an option-like award) that becomes exercisable as it vests.

Key Details

• Transaction date: June 2, 2026; Form 4 filed June 3, 2026 (timely).
• Reported price: $0.00 in the filing; footnote states the reported price basis is the issuer’s closing market price on June 1, 2026 per the Board Compensation Policy.
• Vesting: 25% vests and becomes exercisable on June 2, 2027; the remaining 75% vests in 12 substantially equal quarterly installments thereafter (total multi-year vesting schedule).
• Shares owned after transaction: Not specified in this filing.
• Filing status: Not marked late; standard insider award disclosure.

Context

• This was a compensation grant (award/derivative), not an open-market purchase or sale. The award is subject to service-based vesting and will only be exercisable (and then convertible into ordinary shares) as portions vest; it does not represent immediately tradable shares.